Iq7611放疗增敏治疗肺癌疗效观察

RADIOSENSITIZATION OF LUNG CANCER BY Iq 7611

Iq7611是天津市医药科学研究所研制的醌类成份放射增敏药物。其作用机理初步研究表明可降低细胞氧耗量,增加氧分压;又可降低癌细胞谷胱甘肽的含量,使癌细胞丧失或减少了对射线的防护能力。自1981年9月到1985年3月在我院使用Iq7611同时合并放射治疗肺癌病人30例,与对照组32例对照性观察,取得较好的近期疗效。

Iq 7611, abstract from the Chinese medicinal herbs, has shown radiosen-sitizing effect in experiments, especially under hypoxic condition. It possesses a quinone radical and may lead to radiosensitization by lowering the oxygen consumption or depletion of glutathione in the tumor cells. A prospective randomized clinical trial on the combination of Iq 7611 and radiotherapy for lung cancers as carried out by the authors showed a CR + PR rate of 87% in the combination group and 47% in the control (radiotherapy alone) group (P< 0.05). However, the 1-, 3- and 5-year survival rates of the combination group were 63%, 20% and 13% in contrast to 59%, 9% and Q% of the control group. The difference was not statistically signiticant (P>0.05). Very mild side effects nausea and vomiting, were observed as the toxicity of Iq 7611 was low. Further study is warranted.